Cargando…

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event (irAE) is occurred in various organs and is suggestive to be related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakakibara-Konishi, Jun, Sato, Mineyoshi, Sato, Michiko Takimoto, Kasahara, Kohei, Onozawa, Masahiro, Mizugaki, Hidenori, Kikuchi, Eiki, Asahina, Hajime, Shinagawa, Naofumi, Konno, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378269/ https://www.ncbi.nlm.nih.gov/pubmed/32714828 http://dx.doi.org/10.1016/j.rmcr.2020.101170

Ejemplares similares

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage
por: Shoji, Tetsuaki, et al.
Publicado: (2018)

A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure
por: Ito, Shotaro, et al.
Publicado: (2021)

Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report
por: Takimoto Sato, Michiko, et al.
Publicado: (2020)

Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension
por: Takashima, Yuta, et al.
Publicado: (2022)

Expression of Bim, Noxa, and Puma in non-small cell lung cancer
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2012)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer
por: Takahashi, Hirofumi, et al.
Publicado: (2022)

Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma
por: Nakasuka, Takamasa, et al.
Publicado: (2015)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

High density and proximity of CD8 (+) T cells to tumor cells are correlated with better response to nivolumab treatment in metastatic pleural mesothelioma
por: Yin, Yuting, et al.
Publicado: (2023)

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
por: Tanaka, Takaaki, et al.
Publicado: (2022)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Phrenic Nerve Paralysis as the Initial Presentation in Pleural Sarcomatoid Mesothelioma
por: Makimoto, Go, et al.
Publicado: (2014)

Diffuse pleural thickening and thoracic contraction: An indistinguishable case from malignant pleural mesothelioma
por: Tada, Yuji, et al.
Publicado: (2020)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
por: Sato, Mineyoshi, et al.
Publicado: (2023)

Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma
por: Hashimoto, Masaki, et al.
Publicado: (2022)

Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Extrathoracic Metastases in Pleural Mesothelioma
por: Dagogo-Jack, Ibiayi, et al.
Publicado: (2023)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma
por: Hata, Koichi, et al.
Publicado: (2021)

Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma
por: Naka, Tomoaki, et al.
Publicado: (2016)

γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
por: Furuta, Megumi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nbakspaptn44bllkncege6mqjj